April 10, 2018; 90 (15 Supplement) April 25, 2018
Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005)
Ludwig Kappos, Krzysztof Selmaj, Amit Bar-Or, Giancarlo Comi, Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalbán, Eva Havrdová, James Sheffield, Kartik Raghupathi, Bruce Cree, Jeffrey Cohen
First published April 9, 2018,
Ludwig Kappos
1University Hospital and University of Basel Basel Switzerland
Krzysztof Selmaj
2Medical University of Lodz Lodz Poland
Amit Bar-Or
3Center for Neuroinflammation and Therapeutics, and Multiple Sclerosis Division, University of Pennsylvania Philadelphia PA United States
Giancarlo Comi
4San Raffaele Scientific Institute, Vita-Salute San Raffaele University Milan Italy
Douglas Arnold
5NeuroRx Research and Montréal Neurological Institute, McGill University Montreal QC Canada
Lawrence Steinman
6Beckman Center for Molecular Medicine, Stanford University Medical Center Stanford CA United States
Hans-Peter Hartung
7Heinrich-Heine University Dusseldorf Germany
Xavier Montalbán
8University of Toronto, St Michael’s Hospital Toronto ON Canada
9Cemcat, Vall d’Hebron Hospital, Universitat Autonoma Barcelona Toronto ON Canada
Eva Havrdová
10First Medical Faculty, Charles University Prague Czech Republic
James Sheffield
11Receptos, a wholly owned subsidiary of Celgene San Diego CA United States
Kartik Raghupathi
11Receptos, a wholly owned subsidiary of Celgene San Diego CA United States
Bruce Cree
12UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco San Francisco CA United States
Jeffrey Cohen
13Mellen Center for MS Treatment and Research, Cleveland Clinic Cleveland OH United States
Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005)
Ludwig Kappos, Krzysztof Selmaj, Amit Bar-Or, Giancarlo Comi, Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalbán, Eva Havrdová, James Sheffield, Kartik Raghupathi, Bruce Cree, Jeffrey Cohen
Neurology Apr 2018, 90 (15 Supplement) S36.005;
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 90 no. 15 Supplement S36.005
Print ISSN:
Online ISSN:
History:
- First Published April 9, 2018.
Copyright & Usage:
© 2018
Author Disclosures
- Ludwig Kappos1,
- Krzysztof Selmaj2,
- Amit Bar-Or3,
- Giancarlo Comi4,
- Douglas Arnold5,
- Lawrence Steinman6,
- Hans-Peter Hartung7,
- Xavier Montalbán8,9,
- Eva Havrdová10,
- James Sheffield11,
- Kartik Raghupathi11,
- Bruce Cree12 and
- Jeffrey Cohen13
- Ludwig Kappos1,
- Krzysztof Selmaj2,
- Amit Bar-Or3,
- Giancarlo Comi4,
- Douglas Arnold5,
- Lawrence Steinman6,
- Hans-Peter Hartung7,
- Xavier Montalbán8,9,
- Eva Havrdová10,
- James Sheffield11,
- Kartik Raghupathi11,
- Bruce Cree12 and
- Jeffrey Cohen13
- 1University Hospital and University of Basel Basel Switzerland
- 2Medical University of Lodz Lodz Poland
- 3Center for Neuroinflammation and Therapeutics, and Multiple Sclerosis Division, University of Pennsylvania Philadelphia PA United States
- 4San Raffaele Scientific Institute, Vita-Salute San Raffaele University Milan Italy
- 5NeuroRx Research and Montréal Neurological Institute, McGill University Montreal QC Canada
- 6Beckman Center for Molecular Medicine, Stanford University Medical Center Stanford CA United States
- 7Heinrich-Heine University Dusseldorf Germany
- 8University of Toronto, St Michael’s Hospital Toronto ON Canada
- 9Cemcat, Vall d’Hebron Hospital, Universitat Autonoma Barcelona Toronto ON Canada
- 10First Medical Faculty, Charles University Prague Czech Republic
- 11Receptos, a wholly owned subsidiary of Celgene San Diego CA United States
- 12UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco San Francisco CA United States
- 13Mellen Center for MS Treatment and Research, Cleveland Clinic Cleveland OH United States
Article usage
Disputes & Debates: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Related Articles
- No related articles found.